Review



m 1 atp  (Jena Bioscience)


Bioz Verified Symbol Jena Bioscience is a verified supplier
Bioz Manufacturer Symbol Jena Bioscience manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Jena Bioscience m 1 atp
    M 1 Atp, supplied by Jena Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/m 1 atp/product/Jena Bioscience
    Average 93 stars, based on 3 article reviews
    m 1 atp - by Bioz Stars, 2026-02
    93/100 stars

    Images



    Similar Products

    93
    Jena Bioscience m 1 atp
    M 1 Atp, supplied by Jena Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/m 1 atp/product/Jena Bioscience
    Average 93 stars, based on 1 article reviews
    m 1 atp - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    90
    TriLink n1-methyl-atp
    N1 Methyl Atp, supplied by TriLink, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/n1-methyl-atp/product/TriLink
    Average 90 stars, based on 1 article reviews
    n1-methyl-atp - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    93
    Jena Bioscience m1atp
    M1atp, supplied by Jena Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/m1atp/product/Jena Bioscience
    Average 93 stars, based on 1 article reviews
    m1atp - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    92
    Jena Bioscience n1 methyl pseudouridine
    Overview of in vitro transcription process and chemical modifications of IVT-mRNA used in this study Main steps, and conditional post-transcriptional treatments, which were only applied to samples with cap modifications, i.e., methylation and dephosphorylation, are illustrated at the top panel. Simplified chemistry of IVT-mRNA synthesized and utilized at this study with various cap and/or nucleotide modifications are depicted at the bottom panel. Sequence of synthesis steps applied for cap modified mRNAs are indicated as colored bars corresponding to each synthesis step. Phosphatase treatment step is further indicated with/− or/+ next to sample name. Chemical formula only indicate the main variations among nucleotides as well as cap structures. See <xref ref-type=Figure S1 for precise chemical formula of cap and nucleotide modifications, and for detailed information on chemistry and synthesis process of each sample. pDNA, plasmid DNA; T7 Pol., T7 RNA polymerase; NTs, nucleotides; ARCA, anti-reverse cap analog; Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methyl-cytidine. " width="250" height="auto" />
    N1 Methyl Pseudouridine, supplied by Jena Bioscience, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/n1 methyl pseudouridine/product/Jena Bioscience
    Average 92 stars, based on 1 article reviews
    n1 methyl pseudouridine - by Bioz Stars, 2026-02
    92/100 stars
      Buy from Supplier

    93
    Jena Bioscience n1 methyl atp
    Overview of in vitro transcription process and chemical modifications of IVT-mRNA used in this study Main steps, and conditional post-transcriptional treatments, which were only applied to samples with cap modifications, i.e., methylation and dephosphorylation, are illustrated at the top panel. Simplified chemistry of IVT-mRNA synthesized and utilized at this study with various cap and/or nucleotide modifications are depicted at the bottom panel. Sequence of synthesis steps applied for cap modified mRNAs are indicated as colored bars corresponding to each synthesis step. Phosphatase treatment step is further indicated with/− or/+ next to sample name. Chemical formula only indicate the main variations among nucleotides as well as cap structures. See <xref ref-type=Figure S1 for precise chemical formula of cap and nucleotide modifications, and for detailed information on chemistry and synthesis process of each sample. pDNA, plasmid DNA; T7 Pol., T7 RNA polymerase; NTs, nucleotides; ARCA, anti-reverse cap analog; Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methyl-cytidine. " width="250" height="auto" />
    N1 Methyl Atp, supplied by Jena Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/n1 methyl atp/product/Jena Bioscience
    Average 93 stars, based on 1 article reviews
    n1 methyl atp - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    Image Search Results


    Overview of in vitro transcription process and chemical modifications of IVT-mRNA used in this study Main steps, and conditional post-transcriptional treatments, which were only applied to samples with cap modifications, i.e., methylation and dephosphorylation, are illustrated at the top panel. Simplified chemistry of IVT-mRNA synthesized and utilized at this study with various cap and/or nucleotide modifications are depicted at the bottom panel. Sequence of synthesis steps applied for cap modified mRNAs are indicated as colored bars corresponding to each synthesis step. Phosphatase treatment step is further indicated with/− or/+ next to sample name. Chemical formula only indicate the main variations among nucleotides as well as cap structures. See <xref ref-type=Figure S1 for precise chemical formula of cap and nucleotide modifications, and for detailed information on chemistry and synthesis process of each sample. pDNA, plasmid DNA; T7 Pol., T7 RNA polymerase; NTs, nucleotides; ARCA, anti-reverse cap analog; Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methyl-cytidine. " width="100%" height="100%">

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages

    doi: 10.1016/j.omtn.2022.01.004

    Figure Lengend Snippet: Overview of in vitro transcription process and chemical modifications of IVT-mRNA used in this study Main steps, and conditional post-transcriptional treatments, which were only applied to samples with cap modifications, i.e., methylation and dephosphorylation, are illustrated at the top panel. Simplified chemistry of IVT-mRNA synthesized and utilized at this study with various cap and/or nucleotide modifications are depicted at the bottom panel. Sequence of synthesis steps applied for cap modified mRNAs are indicated as colored bars corresponding to each synthesis step. Phosphatase treatment step is further indicated with/− or/+ next to sample name. Chemical formula only indicate the main variations among nucleotides as well as cap structures. See Figure S1 for precise chemical formula of cap and nucleotide modifications, and for detailed information on chemistry and synthesis process of each sample. pDNA, plasmid DNA; T7 Pol., T7 RNA polymerase; NTs, nucleotides; ARCA, anti-reverse cap analog; Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methyl-cytidine.

    Article Snippet: Hereby, uridine is fully substituted either by Ψ, N1-methyl-pseudouridine (me 1 Ψ) (Jena Bioscience) or 5-methoxy-uridine (5moU) (Jena Bioscience); cytidine is fully substituted by 5meC.

    Techniques: In Vitro, Methylation, De-Phosphorylation Assay, Synthesized, Sequencing, Modification, Plasmid Preparation

    IVT-mRNA double strand content and integrity investigated by dot blot and agarose gel electrophoresis (A) Poly(A) as ssRNA-negative control, and dsRNA positive control were blotted with the same amount as main samples (1,000 ng/dot), next to dsRNA gradient of 4-fold serial dilutions for generating a standard curve for subsequent quantifications and detected by a dsRNA-antibody. Representative dot blots of IVT-mRNAs with different (B) cap modifications, and (C) nucleotide modifications presented side-by-side with denatured agarose gel electrophoresis images of the same samples. Quantified dsRNA for IVT-mRNAs with various cap modifications (D) as well as (E) nucleotide modifications plotted as weight percent of dsRNA content (calculated according to positive control standard curve) to total mRNA amount blotted on membrane for each sample. Error bars indicate SEM for three independently synthesized IVT-mRNA batches blotted on the membrane in duplicates; see <xref ref-type=Figure S2 for uncropped membrane and the gel image. ARCA, anti-reverse cap analog; MT, methyl-transferase; AnP, Antarctic phosphatase; Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methylcytidine. " width="100%" height="100%">

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages

    doi: 10.1016/j.omtn.2022.01.004

    Figure Lengend Snippet: IVT-mRNA double strand content and integrity investigated by dot blot and agarose gel electrophoresis (A) Poly(A) as ssRNA-negative control, and dsRNA positive control were blotted with the same amount as main samples (1,000 ng/dot), next to dsRNA gradient of 4-fold serial dilutions for generating a standard curve for subsequent quantifications and detected by a dsRNA-antibody. Representative dot blots of IVT-mRNAs with different (B) cap modifications, and (C) nucleotide modifications presented side-by-side with denatured agarose gel electrophoresis images of the same samples. Quantified dsRNA for IVT-mRNAs with various cap modifications (D) as well as (E) nucleotide modifications plotted as weight percent of dsRNA content (calculated according to positive control standard curve) to total mRNA amount blotted on membrane for each sample. Error bars indicate SEM for three independently synthesized IVT-mRNA batches blotted on the membrane in duplicates; see Figure S2 for uncropped membrane and the gel image. ARCA, anti-reverse cap analog; MT, methyl-transferase; AnP, Antarctic phosphatase; Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methylcytidine.

    Article Snippet: Hereby, uridine is fully substituted either by Ψ, N1-methyl-pseudouridine (me 1 Ψ) (Jena Bioscience) or 5-methoxy-uridine (5moU) (Jena Bioscience); cytidine is fully substituted by 5meC.

    Techniques: Dot Blot, Agarose Gel Electrophoresis, Negative Control, Positive Control, Synthesized

    Transfection efficiency and EGFP mRNA expression level in macrophages transfected with IVT-mRNA with various cap and nucleotide modifications (A) Representative fluorescent images and (B) flow cytometric density plots indicating EGFP expression in macrophages transfected with low dose and high dose of IVT-mRNA made of either Cap 0 (i.e., ARCA), or Cap 1 (i.e., ARCA + MT, and CleanCap) with and without phosphatase treatment. (C) Quantification of transfection efficiency, and (D) EGFP mRNA expression level in macrophages transfected with low doses and high doses of the different IVT-mRNAs with cap modifications. (E) Representative fluorescent images of macrophages transfected with low doses of IVT-mRNA composed of nucleotides with different chemical modifications. (F) Flow cytometric density plots indicating EGFP expression in macrophages transfected with low dose and high dose of IVT-mRNA with various nucleotide modifications. (G) Transfection efficiency and (H) EGFP mRNA expression level quantified by flow cytometry and plotted in terms of EGFP-positive cells percentage and MFI of EGFP signal among EGFP-positive cell populations, respectively. Poly(I:C) was also transfected in low dose (125 ng∙mL −1 ). For each condition 125 ng∙mL −1 and 500 ng∙mL −1 of IVT-mRNA were used for transfection referred here as low dose and high dose, respectively. Values are presented as mean ± SD. Error bars indicate SD of three independent experiments from three individual donors. Bar = 50 μm. Statistical differences are depicted with ∗∗p < 0.005, ∗∗∗p < 0.001. ARCA, anti-reverse cap analog; MT, methyl-transferase; AnP, Antarctic phosphatase; Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methyl-cytidine.

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages

    doi: 10.1016/j.omtn.2022.01.004

    Figure Lengend Snippet: Transfection efficiency and EGFP mRNA expression level in macrophages transfected with IVT-mRNA with various cap and nucleotide modifications (A) Representative fluorescent images and (B) flow cytometric density plots indicating EGFP expression in macrophages transfected with low dose and high dose of IVT-mRNA made of either Cap 0 (i.e., ARCA), or Cap 1 (i.e., ARCA + MT, and CleanCap) with and without phosphatase treatment. (C) Quantification of transfection efficiency, and (D) EGFP mRNA expression level in macrophages transfected with low doses and high doses of the different IVT-mRNAs with cap modifications. (E) Representative fluorescent images of macrophages transfected with low doses of IVT-mRNA composed of nucleotides with different chemical modifications. (F) Flow cytometric density plots indicating EGFP expression in macrophages transfected with low dose and high dose of IVT-mRNA with various nucleotide modifications. (G) Transfection efficiency and (H) EGFP mRNA expression level quantified by flow cytometry and plotted in terms of EGFP-positive cells percentage and MFI of EGFP signal among EGFP-positive cell populations, respectively. Poly(I:C) was also transfected in low dose (125 ng∙mL −1 ). For each condition 125 ng∙mL −1 and 500 ng∙mL −1 of IVT-mRNA were used for transfection referred here as low dose and high dose, respectively. Values are presented as mean ± SD. Error bars indicate SD of three independent experiments from three individual donors. Bar = 50 μm. Statistical differences are depicted with ∗∗p < 0.005, ∗∗∗p < 0.001. ARCA, anti-reverse cap analog; MT, methyl-transferase; AnP, Antarctic phosphatase; Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methyl-cytidine.

    Article Snippet: Hereby, uridine is fully substituted either by Ψ, N1-methyl-pseudouridine (me 1 Ψ) (Jena Bioscience) or 5-methoxy-uridine (5moU) (Jena Bioscience); cytidine is fully substituted by 5meC.

    Techniques: Transfection, Expressing, Flow Cytometry

    Evaluation of CD80 expression in macrophages, in response to IVT-mRNA transfection with different chemistry Staggered histogram of CD80 levels in macrophages transfected with low doses and high doses of IVT-mRNA with various cap modifications (A), as well as nucleotide modifications (C) along with untransfected, poly(I:C), the dsRNA positive control transfected in low dose, and activated macrophages. Activated cells were treated with LPS/IFN-γ. MFI of CD80 normalized to untransfected cells is indicated for macrophages transfected with low doses and high doses of mRNA with different cap modifications (B) and nucleotide modifications (D). Mock transfection refers to carrier (i.e., LipoMM) without mRNA. For each condition 125 ng∙mL −1 and 500 ng∙mL −1 of IVT-mRNA were used for transfection, referred here as low dose and high dose, respectively. Expression was measured 24 h after transfection. Values are presented as mean ± SD. Error bars indicate SD of three independent experiments from three individual donors (n = 3). ARCA, anti-reverse cap analog; MT, methyl-transferase; AnP, Antarctic phosphatase; Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methyl-cytidine.

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages

    doi: 10.1016/j.omtn.2022.01.004

    Figure Lengend Snippet: Evaluation of CD80 expression in macrophages, in response to IVT-mRNA transfection with different chemistry Staggered histogram of CD80 levels in macrophages transfected with low doses and high doses of IVT-mRNA with various cap modifications (A), as well as nucleotide modifications (C) along with untransfected, poly(I:C), the dsRNA positive control transfected in low dose, and activated macrophages. Activated cells were treated with LPS/IFN-γ. MFI of CD80 normalized to untransfected cells is indicated for macrophages transfected with low doses and high doses of mRNA with different cap modifications (B) and nucleotide modifications (D). Mock transfection refers to carrier (i.e., LipoMM) without mRNA. For each condition 125 ng∙mL −1 and 500 ng∙mL −1 of IVT-mRNA were used for transfection, referred here as low dose and high dose, respectively. Expression was measured 24 h after transfection. Values are presented as mean ± SD. Error bars indicate SD of three independent experiments from three individual donors (n = 3). ARCA, anti-reverse cap analog; MT, methyl-transferase; AnP, Antarctic phosphatase; Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methyl-cytidine.

    Article Snippet: Hereby, uridine is fully substituted either by Ψ, N1-methyl-pseudouridine (me 1 Ψ) (Jena Bioscience) or 5-methoxy-uridine (5moU) (Jena Bioscience); cytidine is fully substituted by 5meC.

    Techniques: Expressing, Transfection, Positive Control

    Cytokine secretion in macrophages transfected with IVT-mRNA with various nucleotide modifications TNF-α secretion was measured (A) 6 h and (B) 24 h after transfection with low doses and high doses of different IVT-mRNA formula. IL-6 secretion was quantified (C) 6 h and (D) 24 h after transfection. IFN-β secretion was investigated (E) 6 h and (F) 24 h upon transfection. Mock transfection refers to carrier (i.e., LipoMM) without mRNA. Poly(I:C) was also transfected in low-dose positive control. For each condition, 125 ng∙mL −1 and 500 ng∙mL −1 of IVT-mRNA were used for transfection, referred here as low dose and high dose, respectively. Values are presented as mean ± SD. Error bars indicate SD of three independent experiments from three individual donors (n = 3). Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methyl-cytidine.

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages

    doi: 10.1016/j.omtn.2022.01.004

    Figure Lengend Snippet: Cytokine secretion in macrophages transfected with IVT-mRNA with various nucleotide modifications TNF-α secretion was measured (A) 6 h and (B) 24 h after transfection with low doses and high doses of different IVT-mRNA formula. IL-6 secretion was quantified (C) 6 h and (D) 24 h after transfection. IFN-β secretion was investigated (E) 6 h and (F) 24 h upon transfection. Mock transfection refers to carrier (i.e., LipoMM) without mRNA. Poly(I:C) was also transfected in low-dose positive control. For each condition, 125 ng∙mL −1 and 500 ng∙mL −1 of IVT-mRNA were used for transfection, referred here as low dose and high dose, respectively. Values are presented as mean ± SD. Error bars indicate SD of three independent experiments from three individual donors (n = 3). Ψ, pseudouridine; me 1 Ψ, N 1 -Methylpseudouridine; 5moU, 5-methoxy-uridine; 5meC, 5-methyl-cytidine.

    Article Snippet: Hereby, uridine is fully substituted either by Ψ, N1-methyl-pseudouridine (me 1 Ψ) (Jena Bioscience) or 5-methoxy-uridine (5moU) (Jena Bioscience); cytidine is fully substituted by 5meC.

    Techniques: Transfection, Positive Control